Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 1:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: clomiphene Clear all
Completed Not applicable Interventional Results available

Study Evaluating the Timing of Intrauterine Insemination in Relation to Positive Home Ovulation Prediction Kit

NCT02294773
View directory record Official record
Conditions
Infertility
Interventions
Intrauterine Insemination, Clomiphene, Letrozole
Procedure · Drug
Lead sponsor
Midwest Fertility Specialists
Industry
Eligibility
21 Years to 39 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Fort Wayne, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Sep 6, 2026, 1:36 AM EDT
Not listed Not applicable Interventional

The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol

NCT04447872
View directory record Official record
Conditions
Infertility, Diminished Ovarian Reserve, IVF
Interventions
Timing of injectable gonadotropins
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 6, 2026, 1:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration

NCT02274181
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
19 Years to 60 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Sep 6, 2026, 1:36 AM EDT
Completed Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism

NCT00962637
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal, AndroGel, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 68 Years · Male only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
18
States / cities
Birmingham, Alabama • Huntsville, Alabama • Carmichael, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Sep 6, 2026, 1:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparison of Two Formulations of Androxal

NCT01984398
View directory record Official record
Conditions
Bioequivalence
Interventions
12.5 mg Androxal Formulation A, 12.5 mg Androxal Formulation B, 25 mg Androxal Formulation A, 25 mg Androxal Formulation B
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2019 · Synced Sep 6, 2026, 1:36 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Androxal in Male Infertility

NCT02160704
View directory record Official record
Conditions
Infertility
Interventions
Enclomiphene citrate, Placebo
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 35 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Sep 6, 2026, 1:36 AM EDT
Completed Phase 2 Interventional Results available

Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Administration

NCT01880086
View directory record Official record
Conditions
Hypogonadism, Opioid-Related Disorders, Male Infertility
Interventions
Clomiphene citrate, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 6, 2026, 1:36 AM EDT
Completed Phase 4 Interventional Results available

Combined Letrozole and Clomid in Women With Infertility and PCOS

NCT02802865
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Infertility
Interventions
Clomiphene, Letrozole
Drug
Lead sponsor
Rachel Mejia
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Sep 6, 2026, 1:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males

NCT01991327
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
Androxal, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Sep 6, 2026, 1:36 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism

NCT01534208
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
31
States / cities
Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 6, 2026, 1:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function

NCT01923870
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 25 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Sep 6, 2026, 1:36 AM EDT
Not listed Phase 4 Interventional

Ovulation Induction With Clomiphene Citrate and Dexamethasone

NCT01856062
View directory record Official record
Conditions
Infertility
Interventions
Placebo, Dexamethasone
Drug
Lead sponsor
San Antonio Military Medical Center
Federal
Eligibility
18 Years to 40 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Sep 6, 2026, 1:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT

NCT01672801
View directory record Official record
Conditions
Unexplained Infertility, Polycystic Ovarian Syndrome, Anovulatory
Interventions
Placebo, Nimodipine
Drug
Lead sponsor
Boston IVF
Other
Eligibility
25 Years to 40 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 6, 2026, 1:36 AM EDT
Active, not recruiting Phase 4 Interventional Results available

Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation

NCT05206448
View directory record Official record
Conditions
Polycystic Ovary Syndrome, PCOS, Infertility
Interventions
Letrozole, Clomiphene Citrate
Drug
Lead sponsor
Rachel Mejia
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Davenport, Iowa • Iowa City, Iowa • West Des Moines, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Sep 6, 2026, 1:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Differential Effects of Clomiphene Citrate in Women Undergoing Superovulation

NCT01291056
View directory record Official record
Conditions
Mood
Interventions
Placebo, Clomiphene
Other · Drug
Lead sponsor
University of Utah
Other
Eligibility
25 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Sep 6, 2026, 1:36 AM EDT
Completed Phase 2 Interventional Results available

Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

NCT01270841
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Placebo, topical testosterone, Androxal
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
21 Years to 65 Years · Male only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
18
States / cities
Garden Grove, California • Sacramento, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2014 · Synced Sep 6, 2026, 1:36 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Endocrinology Profile in Patients Undergoing Clomiphene, Letrozole, and Combination Clomiphene and Letrozole Cycles

NCT02377479
View directory record Official record
Conditions
Infertility
Interventions
Clomiphene, Letrozole
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
1
States / cities
Beachwood, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Sep 6, 2026, 1:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal

NCT01959685
View directory record Official record
Conditions
Pharmacokinetics, Tolerability
Interventions
Androxal, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Sep 6, 2026, 1:36 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

NCT01532414
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Mobile, Alabama • Little Rock, Arkansas • Garden Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 6, 2026, 1:36 AM EDT
Completed Phase 2 Interventional

Clomid in Men With Low Testosterone With and Without Prior Treatment

NCT01904734
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
Clomiphene
Drug
Lead sponsor
Phoenix VA Health Care System
Federal
Eligibility
30 Years to 70 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 6, 2026, 1:36 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction

NCT00213148
View directory record Official record
Conditions
Anovulation
Interventions
Anastrozole 1 mg, Anastrozole 5 mg, Anastrozole 10 mg, Clomiphene Citrate 50 mg, Clomiphene Citrate 100 mg
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 6, 2026, 1:36 AM EDT
Not listed No phase listed Observational

Relationship of the Microenvironment and Male Fertility

NCT04704141
View directory record Official record
Conditions
Male Infertility, Male Hypogonadism
Interventions
Hormone replacement therapy
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Sep 6, 2026, 1:36 AM EDT
Completed Phase 3 Interventional Results available

Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation

NCT01044862
View directory record Official record
Conditions
Pregnancy, Unexplained Infertility
Interventions
Letrozole (aromatase inhibitor), Clomiphene Citrate, Follicle Stimulating Hormone (gonadotropin)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2015 · Synced Sep 6, 2026, 1:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

NCT01923857
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 25 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Sep 6, 2026, 1:36 AM EDT